Elena Élez
Universitat de Vic - Universitat Central de Catalunya · 689 works · 20,515 citations · h-index 59
Top works
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis
- Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
- LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
- Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
- Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.
- Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
- Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
- SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)